ArticleNeurocritical care2022
Trends in Admissions and Outcomes for Treatment of Aneurysmal Subarachnoid Hemorrhage in the United States.
Article in Neurocritical care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06804421 (Late Neurological Ischemic Deficit in Patients Suffering From Subarachnoid Hemorrhage), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Late Neurological Ischemic Deficit in Patients Suffering From Subarachnoid Hemorrhage: Diagnosis and Treatment
Who cites it
24 citing papers in PubMed, 36 citations in OpenAlex.
- Clinical Profile of Neurosurgical Consultations from the Emergency Department : A Retrospective Analysis.Journal of Korean Neurosurgical Society · 2026Article
- Comparison of the predictive performance of machine learning and conventional logistic regression models for poor discharge outcomes in patients with Aneurysmal subarachnoid hemorrhage: A retrospective cohort study.Neurosurgical review · 2026Article
- Lecanemab treatment for mild alzheimer's disease with high risk of cerebral hemorrhage: a case report.BMC neurology · 2026Article
- Serum Albumin-Globulin Ratio and Rupture Status of Intracranial Aneurysms: A Case-Control Study.Journal of inflammation research · 2026Article
- Desflurane combined with ciprofol or esketamine improves postoperative symptoms without compromising early neurocognitive recovery after intracranial aneurysm endovascular coiling.Frontiers in medicine · 2026Article
- Fibromuscular Dysplasia and Intracranial Aneurysms: A Narrative Review of a Dangerous and Underestimated Association.Journal of clinical medicine · 2025Review
- Psychiatric sequelae following aneurysmal subarachnoid hemorrhage: Insights from a high-volume neurosurgical center in northern China.World journal of psychiatry · 2025Article
- Machine learning modeling for outcome prediction of hospitalized patients with aneurysmal subarachnoid hemorrhage.Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences · 2025Article
- High risk and low incidence diseases: Aneurysmal subarachnoid hemorrhage.The American journal of emergency medicine · 2025Review
- Meningeal lymphatic drainage: novel insights into central nervous system disease.Signal transduction and targeted therapy · 2025Review
- TMEM119-positive microglial cells in cerebrospinal fluid, a potential new marker for neuroinflammatory response after aneurysmal subarachnoid hemorrhage.Journal of neural transmission (Vienna, Austria : 1996) · 2025Article
- Anti-Inflammatory Treatment of Subarachnoid Hemorrhage by Self-Assembled Silymarin Nanoparticles.Small science · 2025Article
- National trends in surgical treatment and clinical outcomes among patients with aneurysmal subarachnoid hemorrhage in the Republic of Korea.Journal of cerebrovascular and endovascular neurosurgery · 2025Article
- Evidence-Based Approach to Cerebral Vasospasm and Delayed Cerebral Ischemia: Milrinone as a Therapeutic Option-A Narrative Literature Review and Algorithm Treatment Proposition.Neurology international · 2025Review
- Nimodipine after aneurysmal subarachnoid hemorrhage: shortened treatment in an unselected patient cohort.Brain & spine · 2025Article
- Treatment of Spontaneous Subarachnoid Hemorrhage: A 20-Year National Inpatient Sample Review.Stroke (Hoboken, N.J.) · 2025Article
- Effect ofJournal of traditional and complementary medicine · 2024Article
- CT perfusion-guided administration of IV milrinone is associated with a reduction in delayed cerebral infarction after subarachnoid hemorrhage.Scientific reports · 2024Article
- Monitoring of Perioperative Microcirculation Dysfunction by Near-Infrared Spectroscopy for Neurological Deterioration and Prognosis of Aneurysmal Subarachnoid Hemorrhage: An Observational, Longitudinal Cohort Study.Neurology and therapy · 2024Article
- Potential role of endothelial progenitor cells in the pathogenesis and treatment of cerebral aneurysm.Frontiers in cellular neuroscience · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLifestyle modifications and advances in surgical and endovascular techniques for treating unruptured intracranial aneurysm (UIA) have vastly evolved over the last few decades and may have reduced the incidence of aneurysmal subarachnoid hemorrhage (aSAH). However, the actual impact of these changes on the rates and outcomes of aSAH remain unexplored. Thus, we studied national aSAH admissions and outcome trends and changes of major risk factors over time.
methodsWe queried the National Inpatient Sample between 2006 and 2018 to identify adult patients admitted and treated for UIA or ruptured aneurysm with aSAH. The Cochran-Armitage test was conducted to assess the linear trend of proportion of prevalence, inpatient mortality, hypertension, and current smoking status among aSAH admissions. Multivariable logistic regression was conducted to assess the odds of presenting with aSAH versus UIA, in addition to the odds of inpatient mortality among patients with aSAH.
resultsA total of 159,913 patients presented with UIA and 133,567 presented with aSAH. Admissions for aSAH decreased by 0.97% (p < 0.001) per year. Current smoking and hypertension were associated with higher odds of being admitted for aSAH compared with the treatment for UIA (odds ratio [OR] 1.38, 95% confidence interval [CI] 1.29-1.48; OR 1.15, 95% CI 1.08-1.22, respectively). Compared with White patients, Black patients (OR 1.32, 95% CI 1.21-1.43), Hispanic patients (OR 1.38, 95% CI 1.25-1.52), and patients of other races and/or ethnicities (OR 1.73, 95% CI 1.54-1.95) had a higher chance of presenting with aSAH. Rates of inpatient mortality among aSAH admissions showed no change over time (p = 0.21). Among patients admitted with aSAH, current smoking and hypertension showed an upward trend of 0.58% (p < 0.001) and 1.60% (p < 0.001) per year, respectively.
conclusionsDespite a downward trend in the annual frequency of hospitalizations for aSAH, inpatient mortality rates for patients undergoing treatment of the ruptured aneurysm have remained unchanged in the United States. Smoking and hypertension are increasingly prevalent among patients with aSAH. Thus, efforts to control these modifiable risk factors must be further strengthened.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.